Standard and Emerging Therapeutic Approaches for Thyroid Malignancies

Seminars in Oncology

Volumn 35, Issue 3, 2008, Pages 298-308

  Brown, Rebecca L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; DOXORUBICIN; IODINE 131; MOTESANIB; SORAFENIB; THYROTROPIN; VANDETANIB;

ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIFFERENTIATED THYROID CANCER; DRUG MEGADOSE; DYSPHAGIA; ESOPHAGUS STRICTURE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LOBECTOMY; METASTASIS; MUCOSA INFLAMMATION; PATIENT MONITORING; PHARYNGITIS; PRIORITY JOURNAL; RISK FACTOR; THYROID CANCER; THYROIDECTOMY; TRACHEA STENOSIS;

ALGORITHMS; DRUG DELIVERY SYSTEMS; HUMANS; IODINE RADIOISOTOPES; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 44849130442     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.03.011     Document Type: Article

References (90)

1. Patel K.N., and Singh B. Genetic considerations in thyroid cancer. Cancer Control 13 (2006) 111-118
2. Sosa J.A., and Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol 94 (2006) 701-707
3. American Cancer Society. http://www.cancer.org/docroot/home// 2008
4. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program. http://seer.cancer.gov/2008
5. Burgess J.R., and Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16 (2006) 47-53
6. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. Endocr Pract 7 (2001) 202-220
7. Thyroid Carinoma. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf Accessed March 2007
8. Green F.L., Page D.L., and Fleming I.D. AJCC cancer staging manual. 6th ed. (2002), Springer, New York
9. Sherman S.I., Brierley J.D., Sperling M., et al., National Thyroid Cancer Treatment Cooperative Study Registry Group. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer 83 (1998) 1012-1021
10. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97 (1994) 418-428
11. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
12. Hay I.D., Bergstralh E.J., Goellner J.R., et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114 (1993) 1050-1057
13. DeGroot L.J., Kaplan E.L., Straus F.H., et al. Does the method of management of papillary thyroid carcinoma make a difference in outcome?. World J Surg 18 (1994) 123-130
14. Mazzaferri E.L., and Young R.L. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70 (1981) 511-518
15. Hay I.D., Grant C.S., and Taylor W.F. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102 (1987) 1088-1095
16. Mazzaferri E.L., and Kloos R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86 (2001) 1447-1463
17. Sosa J.A., Bowman H.M., Tielsch J.M., et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228 (1998) 320-330
18. Lamade W., Renz K., Willeke F., et al. Effect of training on the incidence of nerve damage in thyroid surgery. Br J Surg 86 (1999) 388-391
19. Pal T., Vogl F.D., Chappuis P.O., et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 86 (2001) 5307-5312
20. Shattuck T.M., Westra W.H., and Ladenson P.W. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 352 (2005) 2406-2412
21. Schlumberger M., Berg G., Cohen O., et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150 (2004) 105-112
22. Dow K.H., Ferrell B.R., and Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7 (1997) 613-619
23. Robbins R.J., Tuttle R.M., Sonenberg M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11 (2001) 865-869
24. Berg G., Lindstedt G., and Suurkula M. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 25 (2002) 44-52
25. Barbaro D., Boni G., Meucci G., et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88 (2003) 4110-4115
26. Pacini F., Molinaro E., Castagna M.G., et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87 (2002) 4063-4068
27. Park H.M., Perkins O.W., Edmondson J.W., et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4 (1994) 49-54
28. Leger F.A., Izembart M., Dagousset F., et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 25 (1998) 242-246
29. Muratet J.P., Daver A., and Minier J.F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 39 (1998) 1546-1550
30. Fatourechi V., Hay I.D., Mullan B.P., et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?. Thyroid 10 (2000) 573-577
31. Sherman S.I., Tielens E.T., Sostre S., et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78 (1994) 629-634
32. 131I) therapy for thyroid carcinoma. JAMA 283 (2000) 2272-2274
33. 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 52 (2000) 765-773
34. Maxon H.R. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43 (1999) 313-323
35. Tuttle R.M., Leboeuf R., Robbins R.J., et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 47 (2006) 1587-1591
36. Kulkarni K., Nostrand D.V., Atkins F., et al. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16 (2006) 1019-1023
37. Taylor T., Specker B., Robbins J., et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129 (1998) 622-627
38. Robbins R.J., and Schlumberger M.J. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46 Suppl 1 (2005) 28-37
39. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 2892-2899
40. 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 7 (1997) 265-271
41. DeGroot L.J., Kaplan E.L., McCormick M., et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71 (1990) 414-424
42. Hay I.D. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19 (1990) 545-576
43. Hay I.D., Grant C.S., van Heerden J.A., et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112 (1992) 1139-1146
44. Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26 (2002) 879-885
45. Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16 (2006) 1229-1242
46. Hay I.D. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 94 (2006) 692-700
47. Cady B. Seminars in surgical oncology on thyroid cancer. J Surg Oncol 94 (2006) 646-648
48. Biondi B., Filetti S., and Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1 (2005) 32-40
49. Toft A.D. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 345 (2001) 512-516
50. Torlontano M., Attard M., Crocetti U., et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89 (2004) 3402-3407
51. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 1433-1441
52. Spencer C.A. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 89 (2001) 3702-3704
53. Pacini F., Molinaro E., Castagna M.G., et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 3668-3673
54. Frasoldati A., Pesenti M., Gallo M., et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97 (2003) 90-96
55. Lima N., Cavaliere H., Tomimori E., et al. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest 25 (2002) 110-115
56. Pacini F., Fugazzola L., Lippi F., et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 74 (1992) 1401-1404
57. Salvatore G., Giannini R., Faviana P., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 5175-5180
58. Chow S.M., Yau S., Kwan C.K., et al. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer 13 (2006) 1159-1172
59. Lee N., and Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer 13 (2006) 971-977
60. Ronga G., Filesi M., Montesano T., et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging 48 (2004) 12-19
61. Bernier M.O., Leenhardt L., Hoang C., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86 (2001) 1568-1573
62. Luster M., Lippi F., Jarzab B., et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12 (2005) 49-64
63. Robbins R.J., Driedger A., and Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16 (2006) 1121-1130
64. Schlumberger M., Lacroix L., Russo D., et al. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3 (2007) 260-269
65. Pacini F., Agate L., Elisei R., et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86 (2001) 4092-4097
66. Pacini F., Lippi F., Formica N., et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28 (1987) 1888-1891
67. Pineda J.D., Lee T., Ain K., et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80 (1995) 1488-1492
68. Grunwald F., Schomburg A., Bender H., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23 (1996) 312-319
69. Chin B.B., Patel P., Cohade C., et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 91-95
70. Holt E. Controversies in the surveillance of patients with well differentiated thyroid cancer. Curr Opin Oncol 19 (2007) 6-10
71. Bernstein L., and Gurney J.G. Carcinomas and other malignant epithelial neoplasms. http://seer.cancer.gov/publications 2001
72. Hung W.S.N. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 12 (2002) 683-702
73. Jarzab B., Handkiewicz-Junak D., and Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 12 (2005) 773-803
74. Rachmiel M., Charron M., Gupta A., et al. Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab 19 (2006) 1377-1393
75. Zimmerman D., and Lteif A.N. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 27 (1998) 109-126
76. van Tol K.M., de Vries E.G., Dullaart R.P., et al. Differentiated thyroid carcinoma in the elderly. Crit Rev Oncol Hematol 38 (2001) 79-91
77. Bliss R., Patel N., Guinea A., et al. Age is no contraindication to thyroid surgery. Age Ageing 28 (1999) 363-366
78. Baudin E., and Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8 (2007) 148-156
79. Fagin J.A. Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 89 (2004) 4264-4266
80. Trovisco V., Soares P., and Sobrinho-Simoes M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 37 (2006) 781-786
81. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 6373-6379
82. Knauf J.A., Kuroda H., Basu S., et al. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22 (2003) 4406-4412
83. Marks P., Rifkind R.A., Richon V.M., et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 (2001) 194-202
84. Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86 (2001) 3430-3435
85. Milano A., Chiofalo M.G., Basile M., et al. New molecular targeted therapies in thyroid cancer. Anticancer Drugs 17 (2006) 869-879
86. Cohen E.E., Vokes E.E., Rosen L.S., et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. J Clin Oncol 25 Suppl 18, abstr (2007) 6008
87. Sherman S.I., Schlumberger M.J., Droz J., et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). J Clin Oncol 25 Suppl 18, abstr (2007) 6017
88. Kloos R., Ringel M., Knopp M., et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. J Clin Oncol 24 Suppl 18, abstr (2006) 5534
89. Gupta V., Pattaswamy K., Lassoued W., et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. J Clin Oncol 25 Suppl 18, abstr (2007) 6019
90. Wells S.A., Gosnell J.E., Gagel R.F., et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. J Clin Oncol 25 Suppl 18, abstr (2007) 6018